Beta Synuclein Monomers

• Background:

  Alzheimer’s Disease (AD) is the most common neurodegenerative disease, affecting 10% of seniors over the age of 65 (1). It was named after Alois Alzheimer, a German scientist who discovered tangled bundles of fibrils where neurons had once been in the brain of a deceased patient in 1907 (2). Beta synuclein is abundant in neurofibrillary lesions of patients with Alzheimer's Disease. Beta synuclein is suggested to be an inhibitor of alpha synuclein aggregation- protecting the central nervous system from the neurotoxin effects of alpha synuclein (3).

• Description:

  Human Recombinant Beta Synuclein Protein Monomers

• Product Name Alternative:

  14 kDa brain-specific protein, Beta-synuclein Protein, Phosphoneuroprotein 14 Protein, PNP14 Protein, Sncb Protein, Synuclein beta Protein, SYUB_HUMAN Protein

• UNSPSC:

  12352202

• Gene ID:

  6620

• Swiss Prot:

  Q16143

• Accession Number:

  NP_001001502.1

• Cellular Locus:

  Cytoplasm

• Host:

  E. coli

• Origin Species:

  Human

• Target:

  Beta Synuclein

• Conjugation:

  No tag

• Applications:

  WB, SDS-PAGE, In vivo assay, In vitro assay

• Purification Method:

  Ion-exchange Purified

• Concentration:

  2 mg/ml

• Purity:

  >95%

• Weight:

  0.2

• Length:

  Full length

• Buffer:

  PBS pH 7.4

• Molecular Weight:

  14.28 kDa

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For research use only.

• Additionnal Information:

  For corresponding PFFs, see catalog# SPR-457

• References & Citations:

  1. www.alz.org/alzheimers-dementia/facts-figures 2. Alzheimer, A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. Psych.-Gerichtl. Med. 64, 146–148 (1907). 3. Taschenberger G., et al. (2013) Ann Neurol. 74(1): 109-118.